Abstract
The clinical effect of phenoxybenzamine, an .alpha. blocking agent, was studied in a series of 37 patients with varying degrees of neurogenic vesical dysfunction. An overall 78% success rate was achieved, with an 86% success rate in patients with reflex neurogenic bladder. Phenoxybenzamine demonstrates excellent results in patients with neurovesical dysfunction who are unable to empty their bladders by other means, and effectiveness regardless of the level of the lesion, cystometric findings or duration of neurogenic vesical disease.